Click4Assistance UK Live Chat Software
Helpline01322 619898

Emerade adrenaline auto-injectors supply update

We have received the below notice regarding Emerade adrenaline autoinjectors. 

Dear Emerade Adrenaline Autoinjector Users:

 The Medicines & Healthcare products Regulatory Agency (MHRA) has received reports of Emerade pens failing to activate. This means that the needle is not released, and the injection is not delivered.

This is different from the needle blockage issue that you are likely to have been informed about previously by your healthcare professional via a drug alert. This risk is expected to be resolved in all new stock manufactured since July 2019 that will now start to be released to the market.

The cause of the activation failures is being intensively investigated but is currently unknown.

Following discussions with alternative adrenaline auto-injector suppliers there are currently sufficient supplies available to meet historic demand. However, there are insufficient surplus devices to replace all the Emerade pens that would need to be recalled. Therefore, at present, the MHRA is advising that Emerade devices should not be recalled.

The activation failures have not been traced to any particular batches of product.

The MHRA understands that you will be very concerned that the pens in your possession may be affected. It is important to note that based on all the information to date, the majority of pens will activate as normal.

If you do need to use an Emerade pen, as a precaution you should press the pen very firmly against the thigh. If this does not result in activation, you should immediately use your second pen. Information is provided here to illustrate what a non-activated pen looks like.

If a further dose of adrenaline is needed before the emergency services arrive, additional attempts should be made to administer a pen that has failed to activate. This is because reports received suggest that a pen may activate after further attempts. You are reminded to carry two in-date pens with you at all times.

For more information, please refer to the patient information leaflet. There is also a fact sheet with advice on the use of adrenaline auto-injectors which you and your carers are encouraged to read.

 A full investigation is ongoing. The MHRA and Bausch and Lomb UK Limited will provide updated information to healthcare professionals and affected members of the public as soon as it becomes available.

 You can help us by continuing to report any issues directly via the Yellow Card reporting tool,

 Download the free Emerade mobile app. The free Emerade mobile is available for iPhone and Android phones and includes: 

  • Instructions for Emerade
  • Symptoms of anaphylaxis
  • Video demonstration
  • Reminders to carry Emerade at all times

Download the app now by visiting the App Store or Google Play and search for “Emerade”.

 Remember; if you are moved onto a different brand, you must ensure you receive adequate training from your healthcare professional as each product is used differently.

Share this news story